When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EARS - Auris clarifies endpoint for Phase 2/3 study of Keyzilen for tinnitus; shares up 3%
Auris Medical Holding AG
Auris Medical Holding (EARS+3.4%) announces that the FDA and EMA are both on board with the use of the Tinnitus Functional Index (TFI) as the primary efficacy endpoint for its planned Phase 2/3 clinical trial evaluating Keyzilen (AM-101) in patients with the chronic ear-ringing condition.
More news on: Auris Medical Holding Ltd., Healthcare stocks news, Stocks on the move,